Skip to content

EV / sales at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
3.3×-0.1×
Pfizer logo
PfizerPFE
3.5×+0.3×
Immunome logo
ImmunomeIMNM
472×+442×
Arcus Biosciences logo
Arcus BiosciencesRCUS
11.1×+6.1×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
10.5×-17.9×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
308×+215×

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Calculated from Nuvation Bio’s reported figures.

Based on the most recent quarter.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's EV / sales?
Nuvation Bio (NUVB) reported EV / sales of 9.9× in Q1 2026.
How has Nuvation Bio's EV / sales changed year-over-year?
Nuvation Bio's EV / sales decreased by 80.5% year-over-year, from 51.1× to 9.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.